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Introduction {#cam4563-sec-0001}
============

The incidence of malignant melanoma continues to rise with over 230,000 new cases annually worldwide and more than 55,000 deaths estimated in 2012 [1](#cam4563-bib-0001){ref-type="ref"}. Patients with thick primaries, ulcerated lesions, or regional lymph node metastases have a high risk of relapse with 5‐year mortality rates of 40--80% [2](#cam4563-bib-0002){ref-type="ref"}.

To date, interferon alfa‐2b (IFN‐*α*‐2b) is the only therapy that has gained approval in the United States and Europe for the adjuvant treatment of high‐risk resected melanoma. A recent meta‐analysis of 14 randomized controlled trials showed that adjuvant interferon was associated with significantly improved disease‐free survival (*P* \< 0.001) and overall survival (OS) (*P* = 0.002) [3](#cam4563-bib-0003){ref-type="ref"}. Despite this, the optimal dose and treatment duration remain uncertain. It is also unclear whether certain prognostic subgroups (e.g., patients with clinically positive lymph nodes) would derive greater benefit from particular doses or durations of interferon treatment. There is some evidence to suggest that patients with ulcerated tumors derive most benefit from intermediate doses [4](#cam4563-bib-0004){ref-type="ref"}.

A common adjuvant regimen has evolved from the Eastern Cooperative Oncology Group (ECOG) and Intergroup trials [5](#cam4563-bib-0005){ref-type="ref"}, [6](#cam4563-bib-0006){ref-type="ref"}, [7](#cam4563-bib-0007){ref-type="ref"}. The regimen consists of an induction phase of daily intravenous (IV) interferon at 20 MIU/m^2^ per day, which is administered for 5 consecutive days of the 7 for 4 weeks. This is followed by a 48‐week maintenance period, during which subcutaneous interferon is administered at 10 MIU/m^2^ three times per week (SC). In the ECOG/Intergroup 1684, 1690, and 1694 studies [5](#cam4563-bib-0005){ref-type="ref"}, [6](#cam4563-bib-0006){ref-type="ref"}, [7](#cam4563-bib-0007){ref-type="ref"}, dose delays or reductions for toxicity were required in 37%, 44%, and 28% of patients, respectively, during the induction phase and in 36%, 52%, and 37% during maintenance. The survival curves in ECOG1684 [5](#cam4563-bib-0005){ref-type="ref"} separated well before a year, the planned duration of treatment, raising the possibility that the early very high dose component of the regimen drives its efficacy. Three trials have been conducted to examine this question, which have been published elsewhere [8](#cam4563-bib-0008){ref-type="ref"}, [9](#cam4563-bib-0009){ref-type="ref"}, [10](#cam4563-bib-0010){ref-type="ref"}. We present an individual patient data meta‐analysis of these study populations. We aimed to assess whether a shorter duration of high‐dose interferon (HDI) treatment was noninferior to longer treatment in terms of relapse‐free survival, and also to explore patient and tumor characteristics that might impact on outcome and interact with the effects of the drug.

Methods {#cam4563-sec-0002}
=======

Studies eligible for inclusion were those comparing the intravenous month of the ECOG HDI regimen (IV) with the full year of therapy (IV and SC) from which individual patient data were available. Trials databases (clinicaltrials.gov, ISRCTN) and the literature (Pubmed, Cochrane database) were searched using the terms Interferon AND Melanoma AND Adjuvant to identify potential studies. Trials comparing a year of interferon therapy to repeated administration of the IV month were excluded. Three studies were identified from the United Kingdom (U.K.), Greece and China, respectively.

The U.K. phase II trial compared the intravenous month of the ECOG HDI regimen (IV) with the full year of therapy (IV and SC) at the doses described above [8](#cam4563-bib-0008){ref-type="ref"}. In the Greek phase III trial and the Chinese phase II trial, the IV dose was 15 MIU/m^2^ per day and, for those patients receiving a year of treatment, the SC doses used were 10 and 9 MIU three times a week, respectively [9](#cam4563-bib-0009){ref-type="ref"}, [10](#cam4563-bib-0010){ref-type="ref"}. Data were obtained from all three trials on survival and relapse information, trial arm, and the characteristics of gender, age, stage of disease, site of disease, Breslow thickness, and ulceration. Relapse‐free survival (RFS) was calculated as the time from entry into the trial until the date of first relapse or death from any cause. Patients were censored at the date last seen if alive and relapse free. OS was calculated as the time from date of entry in the trial until date of death from any cause.

All analyses were carried out on an intention‐to‐treat basis, including all patients according to their assigned treatment allocation, irrespective of whether they received the treatment or were previously excluded from analyses by the investigators. Due to missing data, multiple imputations were performed using fully conditional specification method [11](#cam4563-bib-0011){ref-type="ref"} within SAS (version 9.3; Cary, NC) statistical package with 10 imputations and the results combined using Rubin\'s rules [12](#cam4563-bib-0012){ref-type="ref"}.

A one‐stage random effects meta‐analysis was performed and the results presented as a hazard ratio (HR) plot. The between study heterogeneity was assessed using the Cochran\'s *Q* statistic [13](#cam4563-bib-0013){ref-type="ref"} and the *I* ^2^ statistic. Due to the low power of any heterogeneity test, a one‐stage random effects Cox regression model was undertaken [14](#cam4563-bib-0014){ref-type="ref"} to assess the treatment effect and treatment--covariate interactions. Multivariable Cox regression models were fitted to investigate the independent predictors of RFS and OS.

With 700 patients, the meta‐analysis had 90% power to determine noninferiority at the 2.5% level with a large 10% noninferiority margin, assuming a 50% RFS at 2 years for the standard IV and SC arm, a recruitment period of 6 years, and a minimum of 2 years follow‐up. Noninferiority of RFS with a 10% margin would be conferred if the 97.5% quantile of the HR is less than 1.32.

Results {#cam4563-sec-0003}
=======

Searching trials and publications databases using the terms Interferon AND Melanoma AND Adjuvant yielded 84 and 205 reports, respectively. The citations in published reports of adjuvant interferon trials were also searched for references to additional studies. From these we identified three studies meeting our criteria, and two additional studies in which a year of treatment was compared to repeated administration of the IV month of the drug.

Data from 716 patients in the three trials were analyzed (Table [1](#cam4563-tbl-0001){ref-type="table-wrap"}). There were differences in the study populations of the three trials. The Chinese population was designed to recruit only patients with acral melanoma, to explore HDI in the prevailing histology in that territory. The U.K. population consisted of a higher proportion with stage III disease (80% vs. 58% or 57%), the majority of which was clinically detectable. More Chinese patients had ulcerated tumors, but median age and gender distribution were similar in the three cohorts.

###### 

Patient characteristics, events, and length of follow‐up by cohort

  Cohort                                            I (U.K.)         II (China)       III (Greece)     Total
  ------------------------------------------------- ---------------- ---------------- ---------------- ----------------
  *Characteristic*                                                                                     
  Sample size                                       194              158              364              716
  Trial arm                                                                                            
  IV                                                96 (49%)         79 (50%)         182 (50%)        357 (50%)
  IV and SC                                         98 (51%)         79 (50%)         182 (50%)        359 (50%)
  Gender                                                                                               
  Female                                            87 (45%)         74 (47%)         180 (49%)        341 (48%)
  Male                                              107 (55%)        84 (53%)         184 (51%)        375 (52%)
  Stage of disease                                                                                     
  II                                                38 (20%)         67 (42%)         110 (30%)        215 (30%)
  III                                               156 (80%)        91 (58%)         207 (57%)        454 (63%)
  Not recorded                                      0                0                47 (13%)         47 (7%)
  Breslow thickness                                                                                    
  ≤1 mm                                             24 (12%)         5 (3%)           13 (3%)          42 (6%)
  \>1--2 mm                                         39 (20%)         15 (9%)          37 (10%)         91 (13%)
  \>2--4 mm                                         53 (27%)         81 (51%)         101 (28%)        235 (33%)
  \>4 mm                                            59 (31%)         57 (36%)         163 (45%)        279 (39%)
  Unknown                                           19 (10%)         0                50 (14%)         69 (9%)
  Ulceration                                                                                           
  Yes                                               72 (37%)         104 (66%)        154 (42%)        330 (46%)
  No                                                63 (32%)         54 (34%)         100 (28%)        217 (30%)
  Unknown                                           59 (30%)         0                110 (30%)        169 (24%)
  Age (years)                                                                                          
  Median (range)                                    49 (17--78)      49 (22--76)      53 (19--83)      50 (17--83)
  Site of primary tumor                                                                                
  Acral                                             13 (7%)          158 (100%)       15 (4%)          186 (26%)
  Head and neck                                     18 (9%)          0                60 (17%)         78 (11%)
  Trunk                                             80 (41%)         0                118 (32%)        198 (27%)
  Limbs                                             75 (39%)         0                138 (38%)        213 (30%)
  Other                                             0                0                14 (4%)          14 (2%)
  Unknown                                           8 (4%)           0                19 (5%)          27 (4%)
  Number alive                                      97 (50%)         70 (44%)         207 (57%)        374 (52%)
  Median follow‐up in years (interquartile range)   5.7 (4.7--7.1)   6.2 (5.9--6.4)   4.7 (2.7--6.3)   5.4 (3.5--6.5)
  Number of deaths                                  97 (50%)         88 (56%)         157 (43%)        342 (48%)
  Number of relapses                                109 (56%)        115 (73%)        217 (60%)        441 (62%)
  Number of relapses or deaths                      113              118              217              448

IV, trial arm receiving IFN‐*α*‐2b 15--20 MIU/m^2^ IV daily 5 days per week for 4 weeks; IV and SC, trial arm receiving IFN‐*α*‐2b 15--20 MIU/m^2^ IV daily 5 days per week for 4 weeks followed by IFN‐*α*‐2b 9--10 MIU/m^2^ administered three times per week for 48 weeks.
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At the time of analysis, the median follow‐up in surviving patients across all trials was 5.4 years (range 0--9.6 years) with 441 (62%) relapses and 342 (48%) deaths (Table [1](#cam4563-tbl-0001){ref-type="table-wrap"}). The proportion of relapses and deaths and length of follow‐up were similar across all three trials (Table [1](#cam4563-tbl-0001){ref-type="table-wrap"}).

There appeared to be no significant heterogeneity between the cohorts with respect to RFS (*χ* ^2^ = 1.1, *P* = 0.59, *I* ^2^ = 0, Fig. [1](#cam4563-fig-0001){ref-type="fig"}). The treatment effect estimate was consistent and nonsignificant across all trials (Table [2](#cam4563-tbl-0002){ref-type="table-wrap"}). The overall HR for relapse or death was 1.16 for the 4 weeks IV arm compared to the IV and SC arm (95% confidence interval \[CI\] 0.89--1.52, Fig. [1](#cam4563-fig-0001){ref-type="fig"}). Noninferiority of the shorter IV arm could not be conferred (*P* = 0.17). Treatment--covariate interactions were explored in a one‐stage random effects model for RFS, but none were significant (Table [3](#cam4563-tbl-0003){ref-type="table-wrap"}). In a multivariable one‐stage random effects analysis, stage (III vs. II, HR = 1.82, 95% CI 1.45--2.28, *P* \< 0.0001), site (acral vs. other, HR = 1.59, 95% CI 1.28--1.96, *P* \< 0.0001), and Breslow thickness (\>4 mm vs. ≤4 mm, HR = 1.16, 95% CI 1.02--1.33, *P* = 0.02) were significant independent predictors of RFS (Table [4](#cam4563-tbl-0004){ref-type="table-wrap"}).

![Hazard ratio plot of the treatment effect for relapse‐free survival.](CAM4-5-017-g001){#cam4563-fig-0001}

###### 

RFS and OS results from the individual patient data analysis for each cohort

  Cohort                  Arm   *N*   No. of events                                                                         Median in years (95% CI)                            \% event free at 2 years   HR (95% CI)         *P*‐value
  ----------------------- ----- ----- ------------------------------------------------------------------------------------- --------------------------------------------------- -------------------------- ------------------- -----------
  Relapse‐free survival                                                                                                                                                                                                        
  I (U.K.)                IV    96    59                                                                                    2.0 (1.2--3.2)                                      50                         1.22 (0.84--1.76)   0.29
  IV and SC               98    54    2.8 (1.5--[a](#cam4563-note-0005){ref-type="fn"})                                     54                                                                                                 
  II (China)              IV    79    64                                                                                    1.5 (0.8--2.4)                                      44                         1.24 (0.86--1.78)   0.24
  IV and SC               79    54    1.9 (1.0--2.8)                                                                        46                                                                                                 
  III (Greece)            IV    182   110                                                                                   2.1 (1.6--3.7)                                      52                         1.01 (0.78--1.32)   0.93
  IV and SC               182   107   2.3 (1.7--3.6)                                                                        52                                                                                                 
  OS                                                                                                                                                                                                                           
  I (U.K.)                IV    96    54                                                                                    3.5 (2.9--[a](#cam4563-note-0005){ref-type="fn"})   67                         1.39 (0.93--2.07)   0.11
  IV and SC               98    43    [a](#cam4563-note-0005){ref-type="fn"}(3.7--[a](#cam4563-note-0005){ref-type="fn"})   71                                                                                                 
  II (China)              IV    79    50                                                                                    5.3 (4.2--5.8)                                      97                         1.44 (0.94--2.20)   0.09
  IV and SC               79    38    5.9 (4.9--[a](#cam4563-note-0005){ref-type="fn"})                                     94                                                                                                 
  III (Greece)            IV    182   78                                                                                    5.4 (4.7--[a](#cam4563-note-0005){ref-type="fn"})   79                         0.91 (0.66--1.24)   0.54
  IV and SC               182   79    5.6 (3.7--[a](#cam4563-note-0005){ref-type="fn"})                                     73                                                                                                 

RFS, relapse‐free survival; OS, overall survival; HR, hazard ratio; IV, trial arm receiving IFN‐*α*‐2b 15--20 MIU/m^2^ IV daily 5 days per week for 4 weeks; IV and SC, Trial arm receiving IFN‐*α*‐2b 15--20 MIU/m^2^ IV daily 5 days per week for 4 weeks followed by IFN‐*α*‐2b 9--10 MIU/m^2^ administered three times per week for 48 weeks.

Limit not reached.
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###### 

Treatment--covariate interactions in a one‐stage random effects model for recurrence‐free survival and overall survival

  Covariate                         *P*‐value for covariate   *P*‐value for treatment--covariate interaction
  --------------------------------- ------------------------- ------------------------------------------------
  Model for relapse‐free survival                             
  Stage                             0.001                     0.60
  Gender                            0.88                      0.27
  Site of disease                   0.03                      0.50
  Breslow group                     0.32                      0.69
  Ulceration                        0.80                      0.70
  Model for overall survival                                  
  Stage                             0.001                     0.96
  Gender                            0.34                      0.98
  Site of disease                   0.64                      0.51
  Breslow group                     0.08                      0.56
  Ulceration                        0.99                      0.78

John Wiley & Sons, Ltd

###### 

Results of a multivariable one‐stage random effects models for relapse‐free survival and overall survival

  Factor                               Hazard ratio   95% confidence interval   *P*‐value
  ------------------------------------ -------------- ------------------------- -----------
  Model for recurrence‐free survival                                            
  Treatment                                                                     0.16
  IV and SC                            1.00                                     
  IV                                   1.14           0.95--1.40                
  Stage                                                                         \<0.0001
  II                                   1.00                                     
  III                                  1.82           1.45--2.28                
  Site of disease                                                               \<0.0001
  Other sites                          1.00                                     
  Acral                                1.59           1.28--1.96                
  Ulceration                                                                    0.99
  Yes                                  1.00                                     
  No                                   1.00           0.80--1.25                
  Breslow thickness                                                             0.02
  ≤4 mm                                1.00                                     
  \>4 mm                               1.16           1.02--1.33                
  Model for overall survival                                                    
  Treatment                                                                     0.26
  IV and SC                            1.00                                     
  IV                                   1.13           0.91--1.41                
  Stage                                                                         \<0.0001
  II                                   1.00                                     
  III                                  2.21           1.66--2.90                
  Site of disease                                                               0.77
  Other sites                          1.00                                     
  Acral                                1.04           0.82--1.32                
  Ulceration                                                                    0.88
  Yes                                  1.00                                     
  No                                   0.99           0.75--1.27                
  Breslow thickness                                                             0.001
  ≤4 mm                                1.00                                     
  \>4 mm                               1.32           1.12--1.56                

IV, trial arm receiving IFN‐*α*‐2b 15--20 MIU/m^2^ IV daily 5 days per week for 4 weeks; IV and SC, trial arm receiving IFN‐*α*‐2b 15--20 MIU/m^2^ IV daily 5 days per week for 4 weeks followed by IFN‐*α*‐2b 9--10 MIU/m^2^ administered three times per week for 48 weeks.

John Wiley & Sons, Ltd

The treatment effect estimate for OS favored the longer IV and SC schedule in two of the studies (Table [2](#cam4563-tbl-0002){ref-type="table-wrap"}). There was some heterogeneity between the cohorts in terms of OS (*χ* ^2^ = 4.1, *P* = 0.13, *I* ^2^ = 51.2, Fig. [2](#cam4563-fig-0002){ref-type="fig"}). The overall HR of death was 1.13 for the IV arm compared to the IV and SC arm (95% CI 0.91--1.39, Fig. [2](#cam4563-fig-0002){ref-type="fig"}). There were no significant treatment--covariate interactions for OS (Table [3](#cam4563-tbl-0003){ref-type="table-wrap"}). In a multivariable one‐stage fixed effects analysis, stage (III vs. II, HR = 2.21, 95% CI 1.68--2.90, *P* \< 0.0001) and Breslow thickness (\>4 mm vs. ≤4 mm, HR = 1.32, 95% CI 1.12--1.56, *P* = 0.001) were significant independent predictors of OS (Table [4](#cam4563-tbl-0004){ref-type="table-wrap"}).

![Hazard ratio plot of the treatment effect for overall survival.](CAM4-5-017-g002){#cam4563-fig-0002}

Discussion {#cam4563-sec-0004}
==========

Patients with stage IIB--IIIC resected melanoma are at high risk of relapse and death. The need for an effective and tolerable adjuvant therapy is paramount. Despite recent advances in melanoma, IFN‐*α* is the only therapy currently licensed for the adjuvant treatment of melanoma, with documented success in improving RFS and, to a lesser extent, OS [3](#cam4563-bib-0003){ref-type="ref"}. There is as yet no universally accepted method of administering IFN‐*α* with wide variations in dose, duration, and intensity of treatment reported in the literature [3](#cam4563-bib-0003){ref-type="ref"}.

For high‐risk patients who are candidates for adjuvant therapy, a commonly accepted regimen consists of a 4‐week induction phase of IFN‐*α*‐2b 20 MIU/m^2^ administered IV 5 days per week for a total of 4 weeks, followed by 48 weeks of maintenance therapy with IFN‐*α*‐2b 10 MIU/m^2^ per day SC administered three times per week.

In a phase II pilot study we published recently [8](#cam4563-bib-0008){ref-type="ref"}, 194 patients with high‐risk resected melanoma were randomized to receive either the IV month of HDI described above or the same regimen followed by 48 weeks of maintenance treatment. We found that OS favored the longer treatment arm. As the study population consisted of a majority of stage IIIB/C patients, this result was consistent with a longer duration of treatment being of greater benefit in a higher risk population.

We have combined these data in a meta‐analysis, together with data from two similar adjuvant HDI studies published previously. All three studies addressed the same question: whether the use of SC interferon for 11 months after a month of higher dose IV administration reduced the risk of melanoma relapse. Although the Greek and Chinese trials used lower starting doses of IFN‐*α*‐2b the greatly reduced frequency of dose interruptions and/or reductions means that all three trials delivered similar total doses of interferon in both the IV alone and IV and SC arms, supporting the combined analysis of the studies.

Disease stage (*P* \< 0.0001), as expected, was a significant predictor of both RFS and OS. Breslow thickness, which is integral to melanoma staging, was also a significant predictor of OS (*P* = 0.001) and had a borderline effect for RFS (*P* = 0.02). We also identified a poorer prognosis for acral disease (*P* \< 0.0001) for RFS compared with other sites, although this was not predictive of OS (acral vs. other *P* = 0.77).

Our analysis was unable to determine that the 4‐week IV induction phase was noninferior at the 10% level for RFS (*P* = 0.17) compared with induction followed by 11 months maintenance therapy. We analyzed results from 716 patients with high‐risk resected melanoma, whereas a definitive assessment of noninferiority that would be likely to change clinical practice would require over 3000 patients with a 5% alpha level and 90% power, assuming a 50% RFS at 2 years in the standard arm, a recruitment period of 6 years, an additional 2 years of follow‐up, and defining noninferiority as no worse than 3%. Nearly all of the benefit of interferon in terms of prolonged RFS, seen in the Mocellin meta‐analysis [3](#cam4563-bib-0003){ref-type="ref"}, has been lost when using only the IV month of HDI (HR = 1.19, 95% CI 0.98--1.45 in multivariate model). This is consistent with the results of the Intergroup E1697 study, designed to compare 4 weeks of adjuvant HDI with observation in patients with intermediate or high‐risk resected melanoma. The trial recruited over 1000 patients (19% with nodal disease), but closed prematurely when interim results showed no difference between the treatment and observation arms [15](#cam4563-bib-0015){ref-type="ref"}.

Although there was no significant evidence for heterogeneity of the treatment effect across the three trials, it is interesting that larger HRs for the month of IV interferon were observed for both RFS and OS within the two studies with the worst prognosis populations. This is in agreement with the stratified analysis within the Chinese study, which showed that median RFS was significantly improved for the stage IIIB--IIIC subset of patients receiving the year long HDI regimen (*P* = 0.02). The Chinese cohort consisted entirely of patients with acral melanoma, whereas 80% of the U.K. group had stage IIIB or IIIC disease.

Despite analyzing individual results from over 700 patients, we have been unable definitively to resolve the issue of whether a month of IV interferon is adequate adjuvant treatment for high or intermediate risk melanoma. This is not altogether surprising, given that the benefits of interferon, such as they are, have only really become discernible through meta‐analyses involving several thousand patients. That being said our results cast doubt on the contention that a month of IV HDI is equivalent to a full year of interferon, with trends consistently favoring the longer course of treatment. Taken together with results from E1697, the available evidence suggests that where adjuvant HDI is being considered there is no reason to deviate from the year long regimen described in the ECOG and Intergroup studies.

The effect of ipilimumab, at the 10 mg/kg dose, on relapse‐free survival in the adjuvant setting has recently been reported [16](#cam4563-bib-0016){ref-type="ref"}. Risk of relapse was significantly reduced with HR estimate 0.75, compared with 0.82 and 0.74 reported for interferon and HDI in meta‐analyses of observation controlled studies [3](#cam4563-bib-0003){ref-type="ref"}, [17](#cam4563-bib-0017){ref-type="ref"}. The impact on OS is not yet known and toxicity was substantial, with nearly 50% of patients stopping ipilimumab because of treatment‐related adverse events. Trials with PD‐1 targeted agents are now under way and the relative merits of these, ipilimumab, and interferon will depend upon the tolerability of regimens. In making this assessment, our data do not provide justification for shorter, less toxic interferon treatment.
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